- ►cardiobarbanza.com [PDF] DM Nathan, JB Buse, MB Davidson, E … - Diabetologia, 2009 - Springer Page 1. CONSENSUS STATEMENT UPDATE Medical management of hyperglycaemia in type
2 diabetes mellitus: a consensus algorithm for the initiation ... Cited by 1039 - Related articles - BL Direct - All 92 versions
DJ Drucker, MA Nauck - The Lancet, 2006 - Elsevier Glucagon-like peptide 1 (GLP-1) is a gut-derived incretin hormone that
stimulates insulin and suppresses glucagon secretion, inhibits gastric emptying,
and reduces appetite and food intake. Therapeutic approaches for enhancing ... Cited by 403 - Related articles - All 10 versions
- ►wanfang.gov.tw [DOC] RE Amori, J Lau, AG Pittas - Jama, 2007 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Add to CiteULike Add to ... Cited by 240 - Related articles - BL Direct - All 8 versions
- ►homestead.com [PDF] JB Dixon, PE O'Brien, J Playfair, L Chapman, … - Jama, 2008 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Context Observational ... Cited by 189 - Related articles - BL Direct - All 10 versions
- ►rh.dk [PDF] LL Baggio, DJ Drucker - Gastroenterology, 2007 - Elsevier This review focuses on the mechanisms regulating the synthesis, secretion,
biological actions, and therapeutic relevance of the incretin peptides
glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ... Cited by 172 - Related articles - All 25 versions
- ►perioimplantelsalvador.com [PDF] BL Mealey, TW Oates - Journal of Periodontology, 2006 - Am Acad Periodontology Background: The purpose of this review is to provide the reader with practical
knowledge concerning the relationship between diabetes mellitus and periodontal
diseases. Over 200 articles have been published in the English literature ... Cited by 160 - Related articles - BL Direct - All 18 versions
M Bayes, X Rabasseda, JR Prous - Methods and findings in experimental and clinical …, 2006 - journals.prous.com Contributing Editors: P. Cole, C. Orellana, JA Vallès, RM a . Antonijoan, KP
Mohana Priya, M. Priya, V. Renuga, R. Sree Lekha, B. Priya, A. Tomillero, G.
Krithiga and E. Banu Rekha. Cited by 148 - Related articles - All 9 versions
MA Nauck, S Duran, D Kim, D Johns, J … - Diabetologia, 2007 - Springer Abstract Aims/hypothesis The aim of this 52-week, open-label, non- inferiority
trial was to compare the safety and efficacy of exenatide (an incretin mimetic)
with that of biphasic insulin aspart. Materials and methods Patients on ... Cited by 132 - Related articles - BL Direct - All 4 versions
- ►diabetesjournals.org D Kim, L MacConell, D Zhuang, PA Kothare, … - Diabetes Care, 2007 - Am Diabetes Assoc RESULTS—From baseline to week 15, exenatide LAR reduced mean ± SE A1C by
−1.4 ± 0.3% (0.8 mg) and −1.7 ± 0.3% (2.0 mg), compared with +0.4 ± 0.3%
with placebo LAR (P < 0.0001 for both). A1C of ≤7% was achieved by 36 and ... Cited by 127 - Related articles - BL Direct - All 5 versions
- ►annals.org [PDF] B Zinman, BJ Hoogwerf, S Duran Garcia, DR … - Annals of internal medicine, 2007 - Am Coll Physicians Background: Exenatide therapy is effective in combination with metformin or
sulfonylureas for treating type 2 diabetes. Thiazo- lidinediones (TZDs) also are
commonly used, but the efficacy of exenatide with a TZD has not been reported. Cited by 119 - Related articles - BL Direct - All 5 versions
